ArticleFrontiers in pharmacology2025
Oxymatrine inhibited the progression of renal cell carcinoma by increasing TOR1AIP1 expression.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SUMOylation-Driven Subtype Heterogeneity and Prognostic Biomarkers in Renal Cell Carcinoma.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The extract of Radix sophorae tonkinensis, known as oxymatrine (OMT), demonstrates anticancer properties. This investigation explored the influence of oxymatrine on renal cell carcinoma (RCC) and elucidated the associated molecular mechanisms, both Methods: RNA-seq was used to evaluate target genes regulated by OMT. The potential target gene TOR1AIP1 was identified, and the expression of TOR1AIP1 was analyzed in RCC cell lines (Caki-1 and 786-O cells) after treatment with OMT. Further functional assays, including Results: We identified TOR1AIP1 as the potential target gene ofOMT. Among the tested compounds, OMT significantly increased the expression of TOR1AIP1 in RCC cells. OMT inhibited RCC progression, including cell proliferation, migration, and invasion, by upregulating TOR1AIP1. Mechanistically, overexpression of TOR1AIP1 in RCC cells markedly inactivated the JNK signaling pathway and suppressed RCC development. Conclusion: Our findings demonstrate that OMT suppresses RCC progression by increasing the expression of TOR1AIP1 and inactivating the JNK signaling pathway. These findings support TOR1AIP1 as a mechanistic mediator of OMT's antitumor effects in RCC models and provide a rationale for further evaluation in physiologically relevant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.